Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 5/20 | 0.61 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | TTK | P33981 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3603166 | 0.85 | CYP2C9 (0.68) | AURKAEPHB4CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL3603167 | 0.85 | CYP2C9 (0.68) | AURKAEPHB4CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL30929914 | 0.81 | CYP2C19 (0.77) | AURKAEPHB4CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL1182507 | 0.81 | CYP2C19 (0.77) | AURKAEPHB4CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL18556741 | 0.75 | CYP2C19 (0.82) | AURKAEPHB4CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL6152995 | 0.75 | CYP2C19 (0.40) | AURKAEPHB4CYP2C19CYP2C9CYP3A4 | |
| Dapivirine SCHEMBL29360285 | 0.75 | CYP2C19 (0.76) | AURKAEPHB4CYP2C19CYP2C9CYP3A4 | |
| Dapivirine SCHEMBL383370 | 0.75 | CYP2C19 (0.76) | AURKAEPHB4CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL27897793 | 0.74 | AURKA (0.64) | AURKAEPHB4CDK2CDK4EGFR | |
| Dapivirine SCHEMBL1181698 | 0.74 | CYP2C19 (0.78) | AURKAEPHB4CYP2C19CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200345733-A1 | Microbicidal Pyrimidine or Triazine Containing Compounds | Janssen Sciences Ireland Unlimited Company (IE) | 2020-11-05 | — | — | US | claimed |
| EP-1567134-B1 | Pharmaceutical compositions comprising a basic drug compound, vitamin E TPGS and a physiologically tolerable water-soluble acid | JANSSEN PHARMACEUTICA NV (BE) | 2019-11-06 | — | — | EP | claimed |
| US-20170100399-A1 | Microbicidal Pyrimidine Or Triazine Containing Compounds | Janssen Sciences Ireland Unlimited Company (IE) | 2017-04-13 | — | — | US | claimed |
| US-20110165093-A1 | MICROBICIDAL PYRIMIDINE OR TRIAZINE FOR PREVENTING SEXUAL HIV TRANSMISSION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-07-07 | — | — | US | claimed |
| US-7935710-B2 | Microbicidal pyrimidine or triazine for preventing sexual HIV transmission | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-05-03 | — | — | US | claimed |
| EP-1505980-B1 | MICROBICIDAL PYRIMIDINE OR TRIAZINE FOR PREVENTING SEXUAL HIV TRANSMISSION | TIBOTEC PHARM LTD (IE) | 2007-10-24 | — | — | EP | claimed |
| US-7241458-B1 | Antiviral compositions | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | claimed |
| US-20060166943-A1 | Microbicidal pyrimidine or triazine for preventing sexual hiv transmission | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-07-27 | — | — | US | claimed |
| US-20060078609-A1 | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water soluble and respectively base | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-13 | — | — | US | claimed |
| EP-1225874-B1 | ANTIVIRAL SOLID DISPERSIONS | JANSSEN PHARMACEUTICA NV (BE) | 2006-02-01 | — | — | EP | claimed |
| WO-2004050058-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING A BASIC RESPECTIVELY ACIDIC DRUG COMPOUND, A SURFACTANT AND A PHYSIOLOGICALLY TOLERABLE WATER-SOLUBLE ACID RESPECTIVELY BASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-06-17 | — | — | WO | claimed |
| WO-2003094920-A1 | MICROBICIDAL PYRIMIDINE OR TRIAZINE FOR PREVENTING SEXUAL HIV TRANSMISSION | TIBOTEC PHARMACEUTICALS LTD (IE) | 2003-11-20 | — | — | WO | claimed |
| EP-1214300-B1 | RATE-CONTROLLED PARTICLES | ABBOTT GMBH & CO KG (DE) | 2003-09-03 | — | — | EP | claimed |
| EP-0945443-B9 | HIV inhibiting pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2003-08-13 | — | — | EP | claimed |
| US-20030083317-A1 | HIV inhibiting pyrimidine derivatives | ANDRIES KOENRAAD JOZEF LODEWIJ (BE) | 2003-05-01 | — | — | US | claimed |
| EP-0945443-B1 | HIV inhibiting pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2003-02-12 | — | — | EP | claimed |
| US-6440986-B2 | VIRICIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2002-08-27 | — | — | US | claimed |
| US-20010011094-A1 | HIV inhibiting pyrimidine derivatives | ANDRIES KOENRAAD JOZEF LODEWIJ (BE) | 2001-08-02 | — | — | US | claimed |
| WO-1999050250-A1 | HIV INHIBITING PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-10-07 | — | — | WO | claimed |
| EP-0945443-A1 | HIV inhibiting pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-09-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345733-A1 | Microbicidal Pyrimidine or Triazine Containing Compounds | SAMHD1, NT5C2, TK1 | AURKA 4266/4885EPHB4 3608/4885CYP2C19 991/4885 |
| US-20060078609-A1 | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water soluble and respectively base | SLC10A1, SLC7A1, SLC26A4 | AURKA 1468/4885EPHB4 3905/4885CYP2C19 247/4885 |
| US-20030083317-A1 | HIV inhibiting pyrimidine derivatives | CBR1, CCR1, CXCR1 | AURKA 4561/4885EPHB4 2633/4885CYP2C19 464/4885 |
| US-20170100399-A1 | Microbicidal Pyrimidine Or Triazine Containing Compounds | SAMHD1, NT5C2, TK1 | AURKA 4314/4885EPHB4 3634/4885CYP2C19 1091/4885 |
| US-20010011094-A1 | HIV inhibiting pyrimidine derivatives | CBR1, CCR1, NR4A1 | AURKA 4654/4885EPHB4 2636/4885CYP2C19 338/4885 |
| US-20110165093-A1 | MICROBICIDAL PYRIMIDINE OR TRIAZINE FOR PREVENTING SEXUAL HIV TRANSMISSION | SAMHD1, NT5C2, TPMT | AURKA 4545/4885EPHB4 3198/4885CYP2C19 689/4885 |
| US-20060166943-A1 | Microbicidal pyrimidine or triazine for preventing sexual hiv transmission | SAMHD1, NT5C2, TPMT | AURKA 4528/4885EPHB4 3254/4885CYP2C19 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.